Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of April 2022, with a filing date of April 8, 2022. The registrant is a foreign private issuer based in Jerusalem, Israel, filing under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing regarding a shareholder meeting and does not contain financial statements.
Material Changes
The filing announces an amended notice regarding the Annual General Meeting of Shareholders, which is now scheduled for May 16, 2022. No material financial changes versus prior periods are disclosed in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the administrative update of the shareholder meeting date. The filing incorporates the amended notice by reference into the Company's Registration Statements on Form F-3 and Form S-8. No specific guidance, outlook, risks, or unusual items are detailed in the text of this Form 6-K.
Key Facts for Investors to Verify
- Verify the details of the amended Annual General Meeting notice (Exhibit 99.1) scheduled for May 16, 2022.
- Confirm the company name is BiondVax Pharmaceuticals Ltd., as the input metadata incorrectly referenced Scinai Immunotherapeutics Ltd.
- Review the referenced Registration Statements (Form F-3 No. 333-240189 and Form S-8 No. 333-239344) for broader corporate context.